MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa2509820

Медицинская библиотека · The New England journal of medicine · 2026

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

Li Ruonan, Pan Hong, Zhang Lele, Ma Jiaxiu, Li Weiwang, Gao Zhen, Fang Liwei, Tian Linzhu, Shen Yucan, Yang Fei, Zhao Jingyu, Nie Neng, Li Jianping, Wang Wenyan, Pan Xinan, Lian Yu, Li Xingxin, Peng Guangxin, Li Liyun, Yu Xiao, Xu Chun, Liu Yanjie, Kuang Zhexiang, Huang Jinbo, Zhao Xin, Ge Meili, Liu Lijun, Chen Shuo, Feng Yi, Chang Alex H, Deng Biping, Dai Min, Huang Lifang, Lv Lulu, Zheng Yizhou, Luo Yuechen, Xiong Haiqing, Shi Jun

СтатьяКлиническое исследование I фазыПеревод в очереди

Аннотация

BACKGROUND

In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is defined by a lack of response to at least three lines of therapy. CD19-directed chimeric antigen receptor (CAR) T-cell therapy results in profound B-cell depletion and may be a useful approach to achieving drug-free remission in multirefractory AIHA.

METHODS

We enrolled patients from a compassionate-use program and those from a phase 1 study who had primary multirefractory AIHA. Each patient received a single infusion of autologous CD19 CAR T cells. The primary objective was to assess the safety profile - the incidence, characteristics, and severity of adverse events, including cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome. Secondary objectives included efficacy and pharmacokinetic features. A complete response was defined by resolution of symptoms, an increased hemoglobin level, and normalization of hemolysis markers. B-cell reconstitution and the origin of relapse were analyzed with flow cytometry, single-cell RNA sequencing, and paired B-cell receptor sequencing.

RESULTS

CD19 CAR T cells were administered to 11 patients - 5 in the compassionate-use program and 6 in the phase 1 study. The median follow-up was 12.2 months (range, 7.3 to 21.9). All patients had a complete response; the median time to a complete response was 45 days (range, 21 to 153). The median duration of drug-free remission was 11.5 months (range, 6.8 to 21.0). Cytokine-release syndrome of grade 1 or 2 in severity occurred in 9 patients, and immune effector cell-associated neurotoxicity syndrome of grade 1 occurred in 1 patient. A total of 15 infections occurred among 7 patients, with no infections of grade 4 or higher. One patient had immune effector cell-associated hematotoxicity of grade 3. In multi-omics assessments of sequential samples, naive B cells were predominant in the reconstituted B-cell population in patients with drug-free remission, and crosstalk between HLA-DRB5+ B cells, CD4+ T cells, and B-cell maturation antigen-expressing long-lived plasma cells contributed to a relapse-specific B-cell niche.

CONCLUSIONS

CD19 CAR T-cell therapy had expected toxic effects and resulted in sustained remission in patients with multirefractory AIHA. (Funded by the National Key Research and Development Program of China and others; ClinicalTrials.gov number, NCT06231368.).

Для цитирования: Li Ruonan, Pan Hong, Zhang Lele, Ma Jiaxiu, Li Weiwang, Gao Zhen, Fang Liwei, Tian Linzhu, Shen Yucan, Yang Fei, Zhao Jingyu, Nie Neng, Li Jianping, Wang Wenyan, Pan Xinan, Lian Yu, Li Xingxin, Peng Guangxin, Li Liyun, Yu Xiao, Xu Chun, Liu Yanjie, Kuang Zhexiang, Huang Jinbo, Zhao Xin, Ge Meili, Liu Lijun, Chen Shuo, Feng Yi, Chang Alex H, Deng Biping, Dai Min, Huang Lifang, Lv Lulu, Zheng Yizhou, Luo Yuechen, Xiong Haiqing, Shi Jun. CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.. The New England journal of medicine. 2026. DOI: 10.1056/nejmoa2509820.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.